8:16 AM ET
8-K
M&A Deal
SpyGlass Pharma Signs $13M M&A Deal with Advanced Vision Science, Inc.
SpyGlass Pharma acquired 100% of the equity of Advanced Vision Science, Inc. (AVS) from Santen Holdings US for approximately $13 million in cash. The deal secures internal manufacturing capacity for the intraocular lenses (IOL) used in SpyGlass's Phase 3 drug delivery system and includes a supply agreement to continue providing products to Santen in Japan.
- Value
- $13M
- Counterparty
- Advanced Vision Science, Inc.